semaglutide deaths and Cardiovascular Outcomes in Obesity without Diabetes Semaglutide cuts risk for worsening

Oral contraceptives may compound the effects of well-known risk factors, such as hypertension, diabetes, hyperlipidemias, age and obesity

State-level Medicaid coverage indicates whether an individual state includes obesity-indicated GLP-1s (Saxenda, Wegovy, and Zepbound) or Type 2 diabetes-indicated GLP-1s (Ozempic, Mounjaro, and Rybelsus) on its formulary or preferred drug list, including non-preferred or restricted coverage

Our program is designed to be accessible to anyone interested in pursuing a healthier lifestyle and achieving their weight loss goals

Researchers at USC Schaeffer recently proposed a value-based price framework for anti-obesity medications that attempts to account for lifetime outcomes across multiple domains

Common Temperature-Related Side Effects on Semaglutide Beyond general cold sensitivity, semaglutide users report specific temperature-related complaints: feeling chilled in air-conditioned spaces, difficulty maintaining warmth during exercise, and increased sensitivity to cold water